Hengrui Pharma Third-Quarter Profit Rises 88.9% on Licensing Deals
China's Jiangsu Hengrui Pharmaceuticals reported an 88.9% increase in third-quarter 2026 profit, driven by income from out-licensing deals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.